AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 17 |
Market Cap | 228.32M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -23.9 |
PE Ratio (ttm) | -0.87 |
Forward PE | n/a |
Analyst | Buy |
Ask | 28.18 |
Volume | 69,086 |
Avg. Volume (20D) | 70,657 |
Open | 21.02 |
Previous Close | 21.19 |
Day's Range | 20.82 - 22.27 |
52-Week Range | 10.00 - 28.42 |
Beta | undefined |
About CDTX
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive...
Analyst Forecast
According to 6 analyst ratings, the average rating for CDTX stock is "Buy." The 12-month stock price forecast is $33, which is an increase of 58.20% from the latest price.
Next Earnings Release
Analysts project revenue of $300.00K, reflecting a -98.29% YoY shrinking and earnings per share of -4.1, making a 412.50% increase YoY.